2026 Rankings
Best Longevity Protocols 2026
Rapamycin, NMN, NAD+, metformin, and exercise compared with a ranking framework that prioritizes evidence, safety, and durable execution.
Quick Picks
Exercise-Centered Longevity Protocol
Nearly all adults aiming for maximal healthspan return with robust evidence.
Metformin-Eligible Longevity Adjunct
Selected users with metabolic-risk context under clinician supervision.
Rapamycin-Informed Clinical Protocol
Highly informed users in specialist care settings with strong risk tolerance and monitoring discipline.
Longevity Protocol Comparison Table
| Rank | Protocol | Difficulty | Effectiveness | Best For |
|---|---|---|---|---|
| #1 | Exercise-Centered Longevity Protocol | 5/10 | 9.4/10 | Nearly all adults aiming for maximal healthspan return with robust evidence. |
| #2 | Metformin-Eligible Longevity Adjunct | 6/10 | 7.8/10 | Selected users with metabolic-risk context under clinician supervision. |
| #3 | Rapamycin-Informed Clinical Protocol | 8/10 | 7.5/10 | Highly informed users in specialist care settings with strong risk tolerance and monitoring discipline. |
| #4 | NAD+ Support Protocol (Nicotinamide Riboside or IV Context) | 6/10 | 6.9/10 | Users prioritizing energy and recovery markers with realistic expectations and budget awareness. |
| #5 | NMN Supplement Protocol | 4/10 | 6.6/10 | Users curious about NAD precursor strategies after foundational protocols are stable. |
Research Context
The market for longevity protocols is crowded with simplified claims. This guide focuses on what actually deserves top priority in 2026 when hype and evidence are separated and organizes the available evidence so readers can compare what was studied, how strong the evidence is, where it may apply, and what important limitations remain.
ProtocolRank uses an editorial evidence-to-decision lens rather than a clinically validated scoring model. Randomized trials, systematic reviews, mechanistic work, observational evidence, practical burden, and known safety constraints can all be relevant, but they do not carry the same weight and they do not automatically transfer from a study population to an individual reader.
Individual response varies with baseline health, sleep, nutrition, medications, training history, age, sex, comorbidities, and the exact formulation or intervention used. A higher editorial position is therefore a starting point for comparison, not a universal recommendation.
Read this page as educational decision support, not medical advice. If an option affects a chronic condition, prescription medication, pregnancy, psychiatric or endocrine history, or another meaningful safety issue, use the evidence here to prepare a better discussion with a qualified clinician rather than to self-prescribe.
Longevity strategy is increasingly fragmented between lifestyle foundations and pharmacologic or supplement experimentation. The highest-return plans are not anti-technology, but they sequence interventions correctly: first build robust behavior architecture, then add targeted adjuncts where evidence and context justify them.
This ranking places exercise first by a wide margin because it has unmatched evidence across lifespan and function. Metformin and rapamycin are ranked as conditional clinical strategies, not universal recommendations. NAD+ and NMN remain interesting but lower-confidence adjuncts for most healthy users.
A practical longevity stack should improve present-day function while reducing long-term risk. Protocols that undermine sleep, recovery, or budget sustainability are poor long-horizon choices even when mechanistic narratives are compelling.
This guide is educational and does not replace clinician-directed care for prescription therapies.
For adjacent supplement research and deeper ingredient context, continue with these related sister-site resources: Alive Longevity: Longevity Supplement Guides and Alive Longevity: Ingredient Deep Dives.
For peptide-specific protocols, visit peakedlabs.com. For longevity deep-dives, visit alivelongevity.com.
How We Ranked These Protocols
Our editorial methodology for longevity ranking compares evidence quality, applicability, downside risk, implementation burden, and the relevance of outcomes such as all-cause risk factors, functional capacity, metabolic markers, safety profile, and adherence over multi-year horizons. These dimensions help organize the literature; they are not a validated clinical prediction model.
Randomized controlled trials and systematic reviews generally provide stronger causal evidence than mechanism studies, uncontrolled observations, anecdotes, or surrogate markers. We also look for whether the studied population, formulation, dose, comparator, and outcome match the claim being made.
Practical burden matters because an intervention that is difficult, expensive, or hard to monitor may be less useful even when the biological rationale is plausible. We penalize interventions with weak human outcome support when they displace proven lifestyle foundations. Any numeric or ordinal ordering on ProtocolRank should be interpreted as editorial prioritization, not a quantified probability of benefit.
Finally, each option sits inside a broader medical and behavioral context. Sleep, nutrition, training, medications, comorbidities, and clinician-supervised care can change both the expected benefit and the risk. The comparison should narrow the questions worth asking; it should not replace individualized review where that review is appropriate.
Evidence hierarchy is explicit: human outcome data and broad reproducibility outrank mechanistic excitement. Animal data and pathway theory are useful for hypothesis generation but are not equivalent to population-level recommendations.
We also score opportunity cost. Expensive low-confidence interventions can reduce investment in exercise, sleep, and nutrition, which lowers total healthspan return. ProtocolRank prioritizes interventions that protect both health outcomes and execution sustainability.
Detailed Protocol Breakdowns
Exercise-Centered Longevity Protocol
A structured mix of zone 2, resistance training, mobility, and recovery-based progression as the core longevity engine.
Best for: Nearly all adults aiming for maximal healthspan return with robust evidence.
Pros
- +Strongest evidence base in longevity
- +High effect across multiple outcomes
- +Improves quality of life and function
- +Scalable across ages and budgets
- +Synergistic with all other protocols
Cons
- −Requires sustained behavior change
- −Program design matters
- −Injury risk if poorly progressed
- −Results depend on consistency
Protocol Analysis
Exercise-Centered Longevity Protocol appears at editorial position #1 because its proposed mechanism is multi-system adaptation across cardiovascular, metabolic, musculoskeletal, and cognitive pathways. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Exercise-Centered Longevity Protocol is: very strong across lifespan, morbidity, and functional-capacity outcomes. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Exercise-Centered Longevity Protocol are: inconsistency and overtraining both reduce long-term return. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: everyone from beginners to advanced users with scalable programming. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Metformin-Eligible Longevity Adjunct
A medically supervised pharmacologic adjunct sometimes used for metabolic longevity goals in specific populations.
Best for: Selected users with metabolic-risk context under clinician supervision.
Pros
- +Strong metabolic rationale
- +Widely available clinical experience
- +Potential long-term risk modification
- +Structured dosing pathways
- +Objective monitoring is feasible
Cons
- −Not universally indicated
- −GI side effects are common
- −Longevity benefit in healthy users remains debated
- −Requires medical supervision
Protocol Analysis
Metformin-Eligible Longevity Adjunct appears at editorial position #2 because its proposed mechanism is improves insulin-signaling context and influences energy-sensing pathways. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Metformin-Eligible Longevity Adjunct is: moderate in metabolic and diabetic contexts, less definitive in healthy populations. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Metformin-Eligible Longevity Adjunct are: self-directed use without indication or GI management can reduce adherence. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: users with clear metabolic risk profile and clinician oversight. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Rapamycin-Informed Clinical Protocol
A specialist-managed mTOR-modulation approach with careful dosing, risk discussion, and biomarker monitoring.
Best for: Highly informed users in specialist care settings with strong risk tolerance and monitoring discipline.
Pros
- +Strong mechanistic longevity interest
- +Large scientific attention
- +Clear monitoring opportunities
- +Potentially high upside in selected users
- +Can be protocolized clinically
Cons
- −Human evidence uncertainty remains
- −Higher risk and complexity
- −Not suitable for self-experimentation
- −Requires specialized medical context
Protocol Analysis
Rapamycin-Informed Clinical Protocol appears at editorial position #3 because its proposed mechanism is mTOR pathway modulation linked to lifespan signals in preclinical models. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Rapamycin-Informed Clinical Protocol is: promising but still developing in human longevity endpoints. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Rapamycin-Informed Clinical Protocol are: enthusiasm from preclinical data can exceed certainty in human long-term outcomes. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: narrow user groups with informed consent and structured monitoring. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
NAD+ Support Protocol (Nicotinamide Riboside or IV Context)
Supplement or clinic-based NAD+ support strategies aimed at cellular energy and recovery-related pathways.
Best for: Users prioritizing energy and recovery markers with realistic expectations and budget awareness.
Pros
- +Popular and widely available
- +Potential energy-support role
- +Can fit recovery-focused routines
- +Multiple delivery options
- +Relatively easy to trial
Cons
- −Cost can exceed benefit
- −Evidence remains mixed
- −Marketing often overstates outcomes
- −Not foundational compared with exercise
Protocol Analysis
NAD+ Support Protocol (Nicotinamide Riboside or IV Context) appears at editorial position #4 because its proposed mechanism is supports NAD-linked redox and mitochondrial processes. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for NAD+ Support Protocol (Nicotinamide Riboside or IV Context) is: mixed with moderate mechanistic support and variable clinical effect sizes. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for NAD+ Support Protocol (Nicotinamide Riboside or IV Context) are: expensive protocols are often continued without measurable benefit. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: users running structured experiments with clear stop rules. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
NMN Supplement Protocol
A supplement-based NAD precursor approach often used in consumer longevity stacks.
Best for: Users curious about NAD precursor strategies after foundational protocols are stable.
Pros
- +Easy to add to routines
- +Large user interest
- +Potential metabolic support role
- +Accessible compared with clinical therapies
- +Flexible trial design
Cons
- −Uncertain magnitude of benefit
- −Quality control varies
- −Can distract from high-impact basics
- −Cost accumulates over time
Protocol Analysis
NMN Supplement Protocol appears at editorial position #5 because its proposed mechanism is supports NAD precursor availability with potential effects on cellular energy pathways. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for NMN Supplement Protocol is: mixed-to-early in humans with ongoing debate around practical impact. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for NMN Supplement Protocol are: long-term use without clear effect can create unnecessary cost and protocol clutter. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: adjunctive experimentation by data-oriented users. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Implementation Playbook
- • Clarify the decision first: define the specific longevity planning outcome you care about and what evidence would meaningfully change your mind.
- • Check whether the evidence matches your situation: population, baseline status, formulation, comparator, duration, and outcome should be close enough to make the result relevant.
- • Separate study protocol from personal instruction. A dose, schedule, or progression used in a paper describes what was studied; it is not automatically appropriate for an individual reader.
- • Review contraindications, medication interactions, pregnancy considerations, laboratory monitoring needs, and other safety constraints before treating an intervention as actionable.
- • Prefer one clearly defined decision at a time so benefits, adverse effects, and confounders are easier to interpret. For medically consequential interventions, make that decision with a qualified clinician.
- • Predefine what would count as useful, ineffective, or concerning and when the decision should be revisited. Avoid extending an intervention simply because it was ranked highly on this site.
- • Step 7: Build a non-negotiable exercise baseline first; this is the anchor intervention around which all other longevity choices should be made.
- • Step 8: Use clinician-supported lab review before any prescription longevity adjuncts.
- • Step 9: Reallocate budget from low-yield experiments to high-yield lifestyle execution when outcome data is unclear.
The Verdict
Exercise-Centered Longevity Protocol holds the first editorial position because it remains the most evidence-dense, scalable, and outcome-rich strategy by a large margin. That is a comparative judgment about the current evidence and practical context, not a prescription or a guarantee of benefit.
metformin-eligible clinical adjuncts is another option worth comparing when its evidence and constraints better match the decision at hand. pathway-focused compounds like rapamycin, NAD+, and NMN should be approached as conditional additions, not replacements for foundational behavior. Treat the ordering as a research aid, then verify population fit, contraindications, alternatives, and objective response with appropriate professional review when the decision is medically consequential.
Related ProtocolRank Articles
Best Biological Age Tests Ranked 2026
Measure whether your longevity protocols are actually working — TruAge epigenetic clock, PhenoAge blood panel, GlycanAge, and more ranked by scientific validity and decision utility.
Best Wearable Health Trackers for Longevity Ranked 2026
Track longevity protocol response with Oura Ring, WHOOP, CGM, Garmin, and Apple Watch — ranked by HRV accuracy, VO2 max tracking, and metabolic signal quality.
Zone 2 Training Protocols Ranked
Attia vs Maffetone vs Norwegian method — aerobic base development is one of the strongest longevity levers in the exercise-first framework.
Best Longevity Supplements for Women Over 50 Ranked 2026
Omega-3, creatine, D3+K2, urolithin A, NMN/NR, CoQ10, sulforaphane, and spermidine ranked for women's healthspan after 50.
Best HRV Protocols Ranked 2026
Zone 2 training, sleep optimization, resonance breathing, cold exposure, and sauna ranked by HRV improvement effect size — HRV is the key daily biomarker for longevity protocol response.
Best Sleep Optimization Protocols Ranked
Sleep is the #2 longevity lever after exercise — ranked protocols for temperature, timing, light, and supplementation.
Best Recovery Devices Ranked 2026
Percussive therapy, compression boots, PEMF, infrared blankets, and sleep cooling systems ranked for recovery impact in a longevity framework.
Sauna Protocols Ranked
Finnish sauna, infrared, and Huberman heat dosing — heat exposure as an adjunctive recovery and longevity resilience strategy.
Blueprint vs Peter Attia Protocol
How two high-profile longevity systems differ in intensity, testing philosophy, and real-world practicality.
Further Reading from Our Sister Sites
Alive Longevity
Alive Longevity: Longevity Supplement Guides
Research-backed supplement explainers and buyer guides for stacking decisions.
Alive Longevity
Alive Longevity: Ingredient Deep Dives
Deep dives on high-interest ingredients like omega-3s, collagen, and magnesium forms.
Alive Longevity
Alive Longevity: NAD+ and Mitochondria Articles
Topic-focused reading for NAD boosters, mitochondrial support, and healthy-aging strategy.
Longevity Protocol FAQ
What is the #1 longevity protocol in 2026?
A structured exercise program combining Zone 2 aerobic training (150+ minutes per week) and progressive resistance training (2–3 sessions per week) remains the highest-confidence longevity intervention by a wide margin. The evidence base spans decades of prospective cohort data showing 30–50% reductions in all-cause mortality for consistent exercisers. No supplement, pharmaceutical, or biohack in 2026 approaches the magnitude and breadth of evidence supporting exercise as the foundation of a longevity strategy. Peter Attia's exercise-first framework and the TAME trial's design both acknowledge this priority ordering.
Is rapamycin proven for healthy longevity in humans?
Rapamycin has the strongest preclinical longevity signal of any compound — it extends lifespan in mice, yeast, worms, and flies through mTOR pathway inhibition. However, human longevity outcome data is still developing. The most relevant human data comes from immunosenescence studies (showing improved immune function in elderly at low doses) and organ transplant pharmacology. As of 2026, rapamycin is used by a small number of longevity-focused physicians in pulsed low-dose protocols, but it remains a high-information, specialist-supervised intervention with meaningful immunosuppression and metabolic side-effect risks. It is not recommended for self-experimentation.
Should I choose NMN or NAD+ IV therapy first?
Neither should be your first investment. Most adults will get more longevity return from optimizing exercise, sleep, and nutrition than from NAD+ precursor supplementation. If you have those foundations in place and want to explore NAD+ support, oral NMN (250–500 mg daily) is the most accessible and cost-effective starting point. NAD+ IV therapy is significantly more expensive ($250–$1,000+ per session) with limited evidence of durable benefit beyond acute energy and recovery effects. Run a 90-day NMN trial with objective tracking (HRV, energy, bloodwork) before considering clinic-based approaches.
Is metformin a universal anti-aging drug?
No. Metformin has strong metabolic rationale and decades of safety data in diabetic populations, but its benefit in metabolically healthy adults for longevity is unproven. The TAME (Targeting Aging with Metformin) trial is specifically designed to answer this question but results are not yet available. Metformin may blunt some exercise adaptations (particularly muscle protein synthesis and mitochondrial response to training) based on several studies, which creates a direct trade-off against the #1 ranked protocol on this list. As of 2026, metformin is most appropriately used in adults with metabolic risk factors under physician supervision, not as a universal anti-aging supplement.
How should I prioritize my longevity budget?
The highest-return longevity investments in order: (1) exercise programming and recovery infrastructure (gym access, coaching, equipment) — this produces the largest measurable healthspan return; (2) sleep optimization (cool sleep environment, consistent schedule, blackout curtains, and if needed, a sleep cooling device); (3) nutrition quality and meal timing; (4) preventive health testing (annual bloodwork, biological age testing, cancer screening); (5) targeted supplementation only after the first four are optimized. Most people spend too much on supplements and too little on exercise adherence and sleep quality. A $50/month gym habit outperforms a $500/month supplement stack for longevity by a very large margin.
Can I run multiple longevity compounds at once?
It is usually more effective to add one intervention at a time with a defined assessment window (typically 60–90 days) so you can attribute any measurable changes to the specific variable you added. Running multiple compounds simultaneously makes it impossible to determine which is working and which is not. This is especially important given the cost and potential interaction risks of pharmacological longevity interventions. If you are running a multi-compound protocol, work with a physician who can help interpret bloodwork and biomarker changes in context.
What supplements actually have longevity evidence?
The supplements with the strongest evidence relevant to healthspan and longevity include: creatine (muscle mass preservation, cognitive function), omega-3 EPA/DHA (cardiovascular, inflammatory markers), vitamin D3+K2 (bone density, immune function), magnesium glycinate (sleep quality, metabolic function), and CoQ10 ubiquinol (mitochondrial function, cardiovascular support). NMN and NAD+ precursors have mechanistic rationale but weaker human outcome data. The key principle is that no supplement replaces the foundational impact of exercise, sleep, and nutrition — supplements are adjuncts that compound lifestyle foundations, not alternatives to them.
How do I measure whether my longevity protocol is working?
The most actionable longevity metrics in 2026 are: (1) VO2 max or estimated cardiorespiratory fitness (the single strongest predictor of all-cause mortality); (2) grip strength and lean muscle mass (functional capacity markers); (3) HRV trend over time (autonomic resilience); (4) fasting glucose, HbA1c, and insulin (metabolic health); (5) ApoB and lipid panel (cardiovascular risk); (6) biological age testing via epigenetic clocks (TruAge, GrimAge) for long-term trajectory assessment. Track these annually or quarterly rather than daily — longevity is a multi-year signal, not a daily metric. Wearable trackers (Oura Ring, WHOOP) are useful for HRV and sleep quality but should be interpreted in context alongside blood biomarkers.